Atlas Antibodies Acquires HistoCyte Laboratories Ltd
February 1, 2021
Atlas Antibodies AB has signed an agreement to acquire UK-based HistoCyte Laboratories Ltd, a maker of cell-line control materials for immunohistochemical assays. The deal combines Atlas's proteome-wide antibody reagent portfolio with HistoCyte's novel control materials to expand diagnostic and research offerings; closing was expected in early March 2021.
- Buyers
- Atlas Antibodies AB
- Targets
- HistoCyte Laboratories Ltd
- Industry
- Medical Devices
- Location
- United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Agilent Technologies Acquires Biocare Medical
March 9, 2026
Medical Devices
Agilent Technologies entered into a definitive agreement to acquire Biocare Medical, a global provider of clinical and research pathology solutions, for $950 million in an all-cash transaction. The acquisition expands Agilent’s pathology portfolio—particularly in immunohistochemistry (IHC)—and is expected to be accretive to Agilent’s top-line growth rate, margin profile, and non-instrument revenue mix in Year 1.
-
BioIVT Acquires BeCytes Biotechnologies
November 4, 2025
Biotechnology
BioIVT has acquired BeCytes Biotechnologies, a Barcelona-based provider of ethically sourced human tissues and primary cell isolation services. The deal expands BioIVT's European footprint and strengthens its capabilities for New Approach Methodologies (NAMs) and ADME research; BeCytes will continue to operate from Barcelona and financial terms were not disclosed.
-
Biogen Acquires Human Immunology Biosciences for up to $1.8B
May 22, 2024
Biotechnology
Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.
-
Atlas Antibodies Acquires evitria
July 28, 2021
Biotechnology
Atlas Antibodies, majority owned by Patricia Industries, has agreed to acquire evitria, a Zurich-based specialist in transient recombinant antibody expression in CHO cells. Sellers include Afinum and co-investor SHS Capital; the deal is expected to close in Q3 2021 and is positioned as an add-on to build an antibody-focused platform under Patricia Industries.
-
Inotiv Acquires HistoTox Labs
April 13, 2021
Healthcare Services
Inotiv, Inc. has entered into an agreement to purchase substantially all assets of HistoTox Labs, a histopathology contract research organization, for $22.0 million in cash. The acquisition (subject to financing and customary closing conditions) expands Inotiv's pathology and histology capabilities, adds a Boulder, Colorado facility with digital pathology and immunohistochemistry capabilities, and is expected to retain all HistoTox employees.
-
Discovery Life Sciences Acquires QualTek Molecular Laboratories
May 5, 2019
Healthcare Services
Discovery Life Sciences (based in Huntsville, Alabama) has acquired QualTek Molecular Laboratories, a provider of CAP/CLIA-accredited and GLP-capable immunohistochemistry (IHC) laboratories in California and Pennsylvania. The acquisition expands Discovery's histopathology and IHC assay development capabilities and integrates QualTek's services with Discovery's biospecimen, sequencing, flow cytometry and multiomic annotation offerings to accelerate biomarker validation and drug/diagnostic development.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.